CERT Company Profile and Key Details
Certara
Price Chart
Stock Price Today
Certara, Inc. (CERT) stock surged +3.19%, trading at $6.80 on NASDAQ, up from the previous close of $6.59. The stock opened at $6.52, fluctuating between $6.07 and $6.83 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 26, 2026 | 6.52 | 6.83 | 6.04 | 6.80 | 4.56M |
| Feb 25, 2026 | 6.71 | 6.75 | 6.46 | 6.59 | 4.05M |
| Feb 24, 2026 | 6.55 | 6.74 | 6.39 | 6.69 | 3.46M |
| Feb 23, 2026 | 6.41 | 6.58 | 6.33 | 6.49 | 1.96M |
| Feb 20, 2026 | 6.54 | 6.76 | 6.46 | 6.46 | 1.94M |
| Feb 19, 2026 | 6.49 | 6.66 | 6.32 | 6.65 | 3.11M |
| Feb 18, 2026 | 6.53 | 6.66 | 6.44 | 6.53 | 3.03M |
| Feb 17, 2026 | 6.66 | 6.82 | 6.50 | 6.51 | 3.43M |
| Feb 13, 2026 | 6.69 | 6.85 | 6.62 | 6.62 | 2.35M |
| Feb 12, 2026 | 7.00 | 7.04 | 6.45 | 6.67 | 4M |
| Feb 11, 2026 | 7.01 | 7.09 | 6.71 | 6.93 | 2.48M |
| Feb 10, 2026 | 7.20 | 7.29 | 6.93 | 7.00 | 2.44M |
| Feb 09, 2026 | 7.26 | 7.26 | 6.97 | 7.17 | 2.92M |
| Feb 06, 2026 | 7.39 | 7.50 | 7.16 | 7.23 | 5.11M |
| Feb 05, 2026 | 7.60 | 7.74 | 7.30 | 7.38 | 4.61M |
| Feb 04, 2026 | 7.75 | 7.96 | 7.55 | 7.61 | 3.47M |
| Feb 03, 2026 | 8.32 | 8.45 | 7.49 | 7.75 | 4.55M |
| Feb 02, 2026 | 8.78 | 8.79 | 8.28 | 8.30 | 2.16M |
| Jan 30, 2026 | 9.16 | 9.22 | 8.74 | 8.79 | 1.74M |
| Jan 29, 2026 | 9.37 | 9.45 | 9.15 | 9.26 | 1.67M |
Contact Details
About Company
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Company Information
| Employees | 1487 |
| Beta | 1.48 |
| Sales or Revenue | $354.34M |
| 5Y Sales Change% | 0.803% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Healthcare Information Services |
Stock Peers
Technical Performance
Shareholding & Insider Activity
Financial & Profitability Overview
On valuation metrics, Certara trades at a P/E of 98.44, P/S of 2.56 and P/B of 1.01. The current ratio is 2.09 and quick ratio is 2.09. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 78.62 days. Debt-to-equity is 0.28, supported by a cash flow-to-debt ratio of 0.32.
Quarterly Financial Highlights
The company ended the quarter with $234.95M in cash and short-term investments, a total debt of $298.19M, and net debt of $63.24M. Total assets were $1.56B, with equity of $1.05B. Financials further reflected stability, with operating cash flow of $82.76M, free cash flow of $67.43M, and capital expenditures of - $15.32M.
Frequently Asked Questions
Chief HR Officer
Prof. Amin Rostami PharmD, Ph.D., FCP
Chief Scientific Officer
Mr. Ron DiSantis
Senior Vice President of Corporation Devel.
Dr. Iain Gardner
Head of Translational Science and Senior Scientific Advisor
Mr. Max Kanevsky
Chief Technology Officer
Dr. William F. Feehery Ph.D.
Chief Executive Officer & Director
Dr. Patrick F. Smith Pharm.D.
Pres of Integrated Drug Devel.
Mr. John E. Gallagher III
Chief Financial Officer
Dr. Frederic Yves Bois
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Ms. Sheila Rocchio MBA
Chief Marketing Officer
Mr. Andrew Schemick
Chief Financial Officer
Mr. M. Andrew Schemick
Chief Financial Officer
Mr. Jaap Mandema
Chief Innovation Officer
Mr. Leif E. Pedersen
Pres & Chief Commercial Officer
Dr. Robert P. Aspbury Ph.D.
Pres of Certara Scientific Software
Mr. Richard M. Traynor
Senior Vice President, Gen. Counsel & Sec.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep